Prevalence of hypertension in 1,795 subjects with chronic renal disease: The modification of diet in renal disease study baseline cohort

Buckalew, Vardaman M.; Berg, Richard L.; Wang, Shin-Ru; Porush, Jerome G.; Sally, Rauch; Schulman, Gerald

doi:10.1016/s0272-6386(96)90380-7

Cited by 206 publications

(111 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These results are similar to previous studies examining blood pressure control in nontransplant CKD (2,17,18). Tonelli et al found that only 42% of patients followed in tertiary care nephrology clinics achieved target blood pressure (18).…”

Section: Discussionsupporting

confidence: 90%

See 1 more Smart Citation

The Burden of Chronic Kidney Disease in Renal Transplant Recipients

Karthikeyan

Karpinski

Nair

et al. 2004

American Journal of Transplantation

139

View full text Add to dashboard Cite

The National Kidney Foundation has developed guidelines for the diagnosis and classification of chronic kidney disease (CKD) but it is not known whether these are applicable to renal transplant recipients. This study determined the prevalence of CKD according to the stages defined in the guidelines, the complications related to CKD and whether the prevalence of complications was related to CKD stage in 459 renal transplant recipients. CKD was present in 412 patients (90%) and

show abstract

Section: Discussionsupporting

confidence: 90%

“…In nontransplant native renal disease, this classification scheme is appropriate as the prevalence of complications increases significantly as the GFR declines (1). Hypertension (2), anemia (3) and hypoalbuminemia (4), to name a few, are all more prevalent at lower levels of GFR.…”

Section: Introductionmentioning

confidence: 99%

The Burden of Chronic Kidney Disease in Renal Transplant Recipients

Karthikeyan

Karpinski

Nair

et al. 2004

American Journal of Transplantation

139

View full text Add to dashboard Cite

show abstract

“…However, CKD occasionally shows a difficult pathologic condition, that is, hyponatremia by traditional diuretics; nonetheless, such diuretics are required for the treatment of volume overload. Volume overload is the main factor of HT that leads to CVD [1]. Hyponatremia is also reported to be associated with increased morbidity and mortality in various diseases, including CKD [8][9][10][11].…”

Section: Discussionmentioning

confidence: 99%

“…Volume overload is a critical problem in chronic kidney disease (CKD) patients because it is one of the main factors that lead to hypertension (HT) and cardiovascular disease (CVD) [1]. Since extracellular volume expansion and total body volume overload result from a failure of sodium and free water excretion in CKD [2], the use of loop and thiazide diuretics that increase sodium excretion is reasonable; however, these diuretics may cause hyponatremia and worse renal function [3].…”

Section: Introductionmentioning

confidence: 99%

Successful treatment with tolvaptan to control blood volume and hyponatremia in a chronic kidney disease patient

et al. 2012

View full text Add to dashboard Cite

We report a case of successful treatment with tolvaptan (15 mg/day) in a 73-year-old female patient with chronic kidney disease (CKD) stage 5 due to diabetic nephropathy and renal sclerosis for volume control and loop diuretic-induced hyponatremia. Her creatinine clearance has remained at 7-10 ml/min for the last 6 months. She was treated by dietary and drug therapy, namely, antihypertensives (nifedipine: 40 mg/day, olmesartan: 20 mg/ day) and loop diuretics (azosemide: 40-120 mg/day), for CKD and concomitant diseases of hypertension and diabetic mellitus. She developed loop diuretic-induced hyponatremia (120 mmol/l) by increased sodium excretion, but the diuretic was required for the control of volume overload. Hence, azosemide was suspended and tolvaptan (15 mg/day) was administered. After tolvaptan treatment, the plasma sodium level gradually increased to a normal level (135-140 mmol/l) and volume overload was improved. Urine volume was maintained at about 1000 ml/ day with low sodium excretion (\40 mmol/day) and increased free water clearance. These results suggest that tolvaptan may be effective for volume control and diureticinduced hyponatremia in CKD patients.

show abstract

“…Decreased kidney function is a component of the pathogenesis of primary hypertension, and chronic kidney disease is the most common cause of secondary hypertension (15). Hypertension is associated with a more rapid progression of kidney damage regardless of the underlying etiology of kidney disease and its presence predicts increased kidneyrelated mortality (16,17).…”

mentioning

confidence: 99%

Longitudinal Study of the National Kidney Foundation’s (NKF) Kidney Early Evaluation Program (KEEP)

Ohmit

Flack

Peters

et al. 2003

Journal of the American Society of Nephrology

View full text Add to dashboard Cite

ABSTRACT. In 2000, the National Kidney Foundation implemented the Kidney Early Evaluation Program (KEEP 2.0) to increase awareness of kidney disease among those at highest risk, and improve outcomes through early detection and referral for care. The KEEP 2.0 screening program identified significant numbers of persons with reduced kidney function, with previously undetected kidney disease risk factors, and with inadequate risk factor control. These data support the evolution to KEEP 3.0, which will continue to identify individuals at high risk for kidney disease, and will address the educational needs of health care providers and consumers, given that preventing and managing kidney disease requires their joint effort. Consumers need to embrace lifestyle behaviors that reduce risk, and adhere to medical recommendations in managing their existing conditions. At the same time, providers need to ensure that the latest evidence-based guidelines in diagnosis and treatment are being implemented in their clinical practice. KEEP 3.0 participants will be randomly assigned to one of several educational programs that vary on whether they provide individually tailored or nontailored information, with long-term follow-up for evaluation of clinical outcomes. Tailored programs may be more successful in supporting behavioral change as these consider the individuals’ “readiness to change.” In addition, participant-identified providers will be randomly assigned to one of several educational protocols designed to provide evidence-based recommendations for clinical and pharmaceutical management of kidney disease and risk factors; these programs vary on whether they require active or passive participation of providers. Analytic evaluations will examine changes from baseline in participant kidney disease and risk factor status during follow-up, and estimate the influence of the various educational protocols on both process of care measures and clinical outcomes. E-mail: jflack@intmed.wayne.edu

show abstract

Prevalence of hypertension in 1,795 subjects with chronic renal disease: The modification of diet in renal disease study baseline cohort

Cited by 206 publications

References 26 publications

The Burden of Chronic Kidney Disease in Renal Transplant Recipients

The Burden of Chronic Kidney Disease in Renal Transplant Recipients

Successful treatment with tolvaptan to control blood volume and hyponatremia in a chronic kidney disease patient

Longitudinal Study of the National Kidney Foundation’s (NKF) Kidney Early Evaluation Program (KEEP)

Contact Info

Product

Resources

About